Haemocomplettan P (Human Fibrinogen)

Haemocomplettan P is a lyophilized powder for solution for injection that contains human fibrinogen as its active ingredient. It is supplied in an unspecified strength and is administered intravenously. The product is classified as a fibrinogen concentrate and is used as a hemostatic agent to replace deficient fibrinogen in the plasma.

Haemocomplettan P is indicated for the replacement of fibrinogen in several clinical situations where low plasma fibrinogen contributes to bleeding risk.

- Congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. - Acquired hypofibrinogenemia associated with liver disease, massive transfusion, or disseminated intravascular coagulation. - Massive hemorrhage where rapid fibrinogen replacement is required. - Surgical or trauma‑related bleeding when fibrinogen levels are below therapeutic thresholds. - Situations where conventional blood components are unavailable or contraindicated.

Side effects of Haemocomplettan P may vary in frequency and severity. Monitoring for any adverse reaction after infusion is recommended.

Common: - Mild fever or chills. - Headache. - Nausea or vomiting. - Transient hypotension. - Local infusion site reactions such as erythema or pain.

Serious: - Allergic or anaphylactic reactions. - Thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism). - Disseminated intravascular coagulation. - Severe hypotension or shock. - Hemolysis or renal impairment.

Before using Haemocomplettan P, clinicians should assess patient history and current clinical status to mitigate risks.

- Verify baseline fibrinogen level and avoid over‑correction. - Use caution in patients with a history of thrombosis or hypercoagulable states. - Monitor for signs of allergic reaction during and after infusion. - Adjust dose in patients with renal or hepatic impairment as needed. - Ensure compatibility with other intravenous solutions. - Maintain aseptic technique to prevent contamination. - Document infusion details and patient response for pharmacovigilance.

Haemocomplettan P may interact with other agents that affect coagulation or immune response.

Avoid: - Concurrent use of pro‑coagulant agents (e.g., activated factor VII) without careful monitoring. - High‑dose anticoagulants that could mask fibrinogen deficiency.

Use with caution: - Other plasma‑derived products (e.g., cryoprecipitate, fresh frozen plasma). - Immunomodulatory drugs that may alter allergic response risk. - Medications that affect renal or hepatic function, requiring dose adjustments. - Blood pressure‑lowering agents if hypotension occurs during infusion.